Mounjaro.Photo:Sandy Huffaker for The Washington Post via Getty
Sandy Huffaker for The Washington Post via Getty
Mounjaro is “significantly” more effective for weight loss than Ozempic, according to a new study.
Mounjaro’s competitor isOzempic, the brand name for semaglutide, which works in the brain to impact satiety and is also FDA-approved to treat Type 2 diabetes. Similar to Mounjaro, Ozempic has been trending due to celebrities using it off-label for weight loss.
Researchers found that patients taking Mounjaro experienced “significantly larger reductions in body weight” while taking the medication compared to patients taking Ozempic.
The large-scale study, which is not yet peer-reviewed, states that patients taking Mounjaro were three times more likely to lose 15% of their body weight than those on Ozempic. Additionally, patients on Mounjaro were six times more likely to lose 10% of their body weight and 1.8 times more likely to lose 5% of their body weight than those taking Ozempic.
Getty
Never miss a story — sign up forPEOPLE’s free daily newsletterto stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories.
“We’ve been able to compare the head-to-head efficacy of these two important medications for weight loss in advance of randomized clinical trials,” Nick Stucky, study author and vice president of Truveta Research, said in astatement. “This study can help to inform patient care and outcomes today, not months from now.”
Both Eli Lilly and Novo Nordisk have other versions of the medications that are approved for weight loss.
Novo Nordisk hasWegovy, another brand name for semaglutide, which was FDA-approved to treat obesity in 2021. Eli Lilly hasZepbound, another brand name for tirzepatide, which was FDA-approved to treat obesity earlier this month.
source: people.com
